Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors

BACKGROUND: Overexpression of Galectin-3 (Gal-3), a β-galactoside binding protein, has been noted in many tumour types but its functional significance and clinical utility in gastric adenocarcinoma (GAC) are not well known. METHODS: We studied 184 GAC patients characterised by histologic grade, sub-...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Br J Cancer
Main Authors: Ajani, Jaffer A, Estrella, Jeannelyn S, Chen, Qiongrong, Correa, Arlene M, Ma, Lang, Scott, Ailing W, Jin, Jiankang, Liu, Bin, Xie, Min, Sudo, Kazuki, Shiozaki, Hironori, Badgwell, Brian, Weston, Brian, Lee, Jeffrey H, Bhutani, Manoop S, Onodera, Hisashi, Suzuki, Koyu, Suzuki, Akihiro, Ding, Sheng, Hofstetter, Wayne L, Johnson, Randy L, Bresalier, Robert S, Song, Shumei
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2018
נושאים:
Translational Therapeutics
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765229/
https://ncbi.nlm.nih.gov/pubmed/29136404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.388
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים